

STANDARD OPERATING PROCEDURE

CALCULATION OF MONTHLY
MAINTENANCE FIGURE (MMF)
IN ECHS POLYCLINICS









19 Feb 2019

SOP ON CALCULATION OF MONTHLY MAINTENANCE FIGURE (MMF) IN ECHS POLYCLINICS

INTRODUCTION

- 1. Refs:-
 - (a) SOP on Medicine Management issued vide CO ECHS letter No B/49762/AG/ECHS/Medicine dated 05 Sep 2017.
 - (b) SOP on Treatment Management in ECHS issued vide CO ECHS letter No B/49770/AG/ECHS/Treatment dated 28 Sep 2018.
 - (c) SOP on Monthly Stock Taking of Medicines issued vide CO ECHS letter No B/49762/AG/ECHS dated 14 Jan 2019.
 - (d) Common Drug List (CDL) issued by O/o DGAFMS vide their letter No 19180/DGAFMS/DG-2C/CDL dated 19 Apr 2016 (**Encl 1**).
- 2. The medicines for ECHS beneficiaries are procured by the respective SEMOs giving cover to the Polyclinics while dental stores are procured by respective SEDOs depending on the approved MMF projected by the PCs. Hence the quantity of medicines demanded and stocked by the SEMOs directly depends on the correctness of MMF calculated by the PCs. There is a need to streamline the procedure for calculation of MMF by the ECHS PCs so that optimum level of medicines are maintained in the PCs and desired beneficiary satisfaction is achieved. Non calculation of correct MMF affects provisioning as well as user satisfaction and the same has been one of the primary reasons of clientele dissatisfaction.

AIM

3. To lay down the broad guidelines for calculation of MMF in ECHS Polyclinics.

ISSUES AFFECTING CALCULATION OF MMF

4. **Gen.** SEMOs/SEDOs procure and manage medicines for various service hosps/ establishments. In addition; they also provision, acct and issue medicines to ECHS patients in service hospitals as well as ECHS Polyclinics. SEMOs calculate avg expdr of 10 months (Jan-Oct) to calculate avg consumption as MMF, however, in ECHS; MMF will be calculated as an average of 12 months (Jan-Dec) as the variations spread over 12 months period capture the expdr pattern more objectively. A deliberate effort is needed to keep the inventory smaller, avoid expiry of medicines and attempt 100% clientele satisfaction.

- 5. **Factors Influencing MMF**. Some of the factors which influence calculation of MMF are as follows:-
 - (a) Disease pattern.
 - (b) Seasonal variations.
 - (c) Monthly drug consumption.
 - (d) Variation in clientele str.
 - (e) Changing of drugs by Med Offrs/ Doctors of hospitals.
 - (f) Regulatory Control/ Changes due to banning of certain combination medicines/ other medicines.
- 6. <u>Calculation of Inflated MMF</u>. Some of the reasons for inflated MMF are as follows:-
 - (a) Fear of medicine not being supplied for a particular period and hence Polyclinic trying to over stock medicines by indicating higher figures despite low consumption.
 - (b) Substitute medicine issued is not properly accounted for.
 - (c) Some medicines of different dosage issued but not factored in the accounting e.g. 2 x Atorvastatin 10 mg is issued when Atorvastatin 20 mg is NA which is not taken into account.
 - (d) Blindly taking monthly expense from the system as actual expenditure whereas medicine issued to other Polyclinics in bulk/ returned to SEMO is not taken into acct.
 - (e) Medicines charged off for any other reason except when issued to patients being factored in average calculation.
 - (f) Medicine segregated in between the period of calculation when taken into acct.
- 7. <u>Calculation of Reduced MMF</u>. Some of the reasons for calculation of reduced MMF is based on the following factors:-
 - (a) Medicine exhausted in the middle of the month is taken as expenditure for that month. Medicine stock if exhausted in middle of the month will show reduced MMF on avg being taken.
 - (b) NA medicine/ medicines provided as substitute/medicines of different weightage is not taken into acct correctly.
 - (c) When surplus medicine (returned by patients) not taken on charge and issued to patients, hence actual expenditure is not known.

(d) When a medicine is having 'zero' balance but still being factored in average calculation.

8. Surplus/Defi of Medicines.

- (a) Issue of alternate medicine (for eg various types of calcium tab avl) makes one type of medicine defi and other surplus. Proper docu is essential.
- (b) Due to shortage of space in pharmacy, all medicines are not kept alphabetically which makes it difficult to get them from bulk store as these are at times dumped at a corner which is inaccessible. Hence correct medicines not provided to the patients though it gets deducted from the ledger balance which factors prescription based accounting. Stocking must be therefore done so as to facilitate ease of access and issued as highlighted in SOP of Monthly Stock Taking issued on 14 Jan 19.
- (c) Inaccurate entries due to software issues.

PROCEDURE FOR CALCULATION OF MMF

- 9. <u>Method of Stocking/ Documentation of Medicines.</u> It has been reiterated in various documents that medicines should be stocked alphabetically but the same has neither been understood nor the advantages intended are being derived. This aspect is being reiterated:-
 - (a) All lists to include monthly STB, MMF, Demands, CRVs, Ledgers, Returned medicine box entries in register, CIVs etc will be also maintained alphabetically for all the entries existing in the said documents.
 - (b) Alphabetic sequencing will be based on alphabetic dictionary sequencing viz if all medicines with 'A' are to be listed before other alphabets, then, within medicines starting from A, sequencing will be decided by sec alphabet viz Aa... will be listed prior to Ab... Similarly, if first two alphabets are also same, the same will be decided by third alphabet and the similar sequencing will continue. Exact dictionary sequence will be followed.
 - (c) Stocking of medicines alphabetically will then be based on exact sequence of monthly STB list as only then intended purpose of quick checking & faster access will be ensured.
 - (d) If there are only five entries in a docu, the alphabetic sequencing within those entries will also be ensured viz if there are five medicines taken out from drop box on a day, these will be entered in the register on that date with alphabetical sequence and similarly for other days. This will assist in making monthly summary for preparation of CRV.
 - (e) If some medicine is in more than one potency, lower potency will be sequenced first viz Metformin 500mg and Metformin 1000mg tablets, Metformin 500mg will be listed prior to Metformin 1000mg.

- (f) All medicines will be sequenced with 'salt name' and not as per 'brand name'.
- (g) Common alphabetical sequence of entire documents will result in ease of acctg and effective checks.

10. **Essential Guidelines**.

- (a) Single ledger will be maintained for accounting of all medicines and expendable consumables. Medicines should be taken on charge as highlighted in SOP on Monthly Stock Taking of Medicines issued on 14 Jan 2019. Entries should be made as explained vide Para 9 above.
- (b) Only that expenditure of medicine should be factored for calculation of MMF which has been issued to patients. Charged off/ issued to SEMO/ other Polyclinics will not be treated as 'expdr' for the purpose of calculation of MMF.
- (c) If there is 'zero' bal of a medicine in a particular month, it should not be included in 'average calculation'.
- (d) If medicine balance reaches 'NIL' at any date in the middle of month, data of that month should not be taken for average calculation.
- (e) There are certain medicines which might be used rarely/ infrequently, such medicines though shown in calculation, should not be finally included in MMF list so that inventory is not unnecessarily enlarged and wastage of these medicines is avoided. If at some stage, some patient needs these medicines, same can be provided through ALC.
- (f) If some medicine has been banned by itself or in combination form, same should not be included in final MMF.
- (g) Once the monthly average is calculated in the above said manner, a conf should be held at Polyclinic level to incl OIC Polyclinic, all MOs, all DOs and all Para Med & Para Dental staff to factor ground variations. Figures arrived in monthly average should be increased/ decreased by an assessed percentage viz increase of certain antidiabetic/ antihypertensive medicines due to continuously increasing occurrence or reduction in certain category viz some patients moved out from the concerned Polyclinic should be factored. Increase/ decrease percentage could be different for each medicine but must be limited between 0 to 10% of monthly average. Any higher variations should be justified with entry in 'remarks' column.
- (h) Monthly average should be mod by increase/ decrease as stated to reach fresh figure after factoring increase/ decrease percentage and the same should be recorded.
- (j) Once this figure is arrived at, it should be taken to closest smaller packing by increasing/ decreasing the No viz if MMF so calculated is 290 but smallest pack has 50 tablets, it should be taken to 300 for ease of procurement at SEMO/SEDO end. However, it may not be always possible since packing comes in

different forms by different companies. Such information may not be available at Polyclinic end. In case of such variations/ inputs not available at PC end, MMF should be kept in closest multiple of '5' or be left at the value calculated.

- (k) If patients require certain medicine in higher potency viz if certain No of patients want Atorvastatin 20mg tablets, these should be also demanded and included in MMF as against having Atorvastatin 10mg tablets only and issuing two x 10mg tablets in place of single 20mg tablet. While it may be medically right but lower potency tablets when compared with higher potency tablets come at approx 30 to 40% costlier.
- (I) Unnecessary long lists should be avoided. A list prepared by O/o DGAFMS and issued vide their letter No 19189/DGAFMS/DG-2C/CDL dt 19 Apr 16 is encl at Encl 1. SEMOs/ SEDOs should prepare such lists for their PCs from these or based on requirement of patients of their PCs. Only those medicines should be included which are needed by patients as requirement is dynamic. No medicines should be included in the list of MMF unless it is required by the patients. Decision of SEMO and SEDO will be final.
- (m) 'Generic name' of drugs should be used to prepare the MMF as against the 'branded name'. Format could be modified subject to basic fields being included.
- (n) Sample calculation sheet alongwith format of MMF is enclosed at Encl 2 alongwith detailed explanation.
- 11. <u>Constitution of Board for MMF</u>. Stn HQ will convene an yearly board as per following composn for calculation of MMF:-
 - (a) **Presiding Offr**. OIC/ Offg OIC Polyclinic.
 - (b) Members.
 - (i) Med specialist (where avlb).
 - (ii) Gynecologist (where avlb).
 - (iii) Medical Officer (MO).
 - (iv) Dental Officer (DO) (where avlb).
 - (v) 1 x Pharmacist (Nursing Asst where Pharmacist NA).
 - (vi) 1 x Para Dental Staff (where DO NA).
 - (vii) Rep of SEMO as covered in Para 12 below.
 - (viii) Members can be increased/ decreased by Stn HQ in convening order based on functional constraints, however, if the above pers are avlb, these will be detailed.

- 12. <u>Vetting of MMF by SEMO</u>. SEMO/SEDO will be finally responsible for vetting of MMF prior to provisioning action is undertaken. This has also been highlighted at Para 8 of SOP on Medicine Mgt issued on 05 Sep 17. This vetting can be done by one of the following methods:-
 - (a) Co-opting MO nominated by SEMO from service hosp at the time of calculation of MMF as per Para 11 (b)(vii). If this option is exercised, the MMF will be mod by SEMO rep and the same will be fwd & copy of the same will be maint at ECHS Polyclinic.
 - (b) MMF calculated data by BOO at PC as per Para 11 once fwd to SEMO, the same is mod at that end. In case values are modified, the mod values will be intimated to Polyclinic also for their records.
 - (c) Each ECHS Polyclinic will be given a copy of approved MMF by controlling SEMO & SEDO for their records copy of which will also be maintained at ECHS Cell at Stn HQ.

13. **Schedule of Prep of MMF**.

- (a) MMF will be calculated based on average of one year (12 months) to capture the variation more objectively preferably from Jan to Dec.
- (b) MMF will be sent to SEMO by seventh of Jan every year for the preceding year which should be the basis for procurement for next FY viz MMF covering the period from Jan to Dec 18 should be fwd by 07 Jan 19 to SEMO for procurement of medicines for FY 19-20 (01 Apr 19 to 31 Mar 20). Calculation done for FY 19-20 will also be revised as per this SOP and details will be forwarded to SEMO/SEDO for approval and procurement.
- (c) In case any SEMO wants MMF data prior to 07 Jan due to addl time required for processing of documents with IFA and subsequent process, he will intimate concerned Polyclinics in writing indicating the month in which MMF is required viz if SEMO wants MMF in Nov 18 for procurement for medicines for FY 19-20 (01 Apr 19-31 Mar 20), the MMF will be sent to SEMO by 07 Nov 18 covering preceding 12 months from Nov 17 to 31 Oct 18. Format of months given at Encl 2 will be accordingly modified.
- (d) **MMF will be prepared only once a year** whereas demands will be fwd on monthly/ quarterly / emergent basis based on various functional aspects between SEMO/SEDO and PCs concerned.

DEMAND OF MEDICINES

14. MMF will be calculated on yearly basis for provisioning purpose, however, demand of medicines will be forwarded factoring the existing stocks. While demand must factor the realistic need, unnecessary demands should be curtailed. Demand should not be exaggerated for overstocking to cater for contingencies when medicine is

in short supply. Demand format could be as under (however, the same could be modified as per reqmt of SEMO/SEDO till it includes these essential columns):-

Ser No	Ledger Vol/ Page No	PVMS No/NIV	Cat	Nomenclature	MMF	Stock avlb (as per last MSTB)	Demanded Now	Supplied by SEMO	Remarks

- 15. NA medicines obtained through ALC in a month will be added in next demand to SEMO/SEDO so that these are available at lesser costs.
- 16. It will be ensured that medicines when received at pre-designated location still have minimum 5/6th of shelf life balance. Eg if a medicine/expendable store has 12 months shelf life, when it reaches SEMO/SEDO, it should be having at least 10 months balance shelf life. This should be followed for all Indian manufactured medicines. In case of imported medicines (which should be the least in No), balance shelf life of minimum 60% should be accepted. This has been allowed due to transit delays. Supply order should be explicitly stating these facts. Supply order should clearly mention that those slow moving/ non consumed medicines can be returned to the vendors minimum three months before expiry date for clean exchange. OIC Polyclinic will ensure that this provision is utilized to ensure that there is 'zero' wastage of the medicines supplied on this count. OIC Polyclinic should intimate details of those medicines with balance shelf life of four months which cannot be consumed so that SEMOs/SEDOs can ensure clean exchange of medicines three months prior to them getting expired.

CONCLUSION

17. The correct calculation of MMF is the responsibility of the Polyclinics. OIC PC will be required to work out the regnt of medicines by correctly calculating MMF and project it timely to the SEMO/SEDO. The MMF will be reviewed by SEMO/SEDO to factor in the actual expenditure and consumption pattern. Correct MMF will ensure efficient procurement by the SEMO/SEDO and achieve the optimum patient satisfaction.

File No : B/49762/AG/ECHS Central Organisation, ECHS Adjutant General's Branch

IHQ of MoD (Army) Thimayya Road, Near Gopinath Circle

Delhi Cantt - 110010

Date: Peb 2019

Distr

AG Coord (a) DGDC & W Sectt

for info pl.

(DK Dubey)

for MD ECHS

Gp Capt

Dir (Med)

O/o DGAFMS DGMS (Army) DGMS (Air) DGMS (Navy) **DGDS** IHQ of MoD (Navy)/Dir ECHS (N) DAV, Subroto Park HQ Southern Command (A/ECHS) HQ Eastern Command (A/ECHS) HQ Western Command (A/ECHS) HQ Central Command (A/ECHS) HQ Northern Command (A/ECHS) HQ South Western Command (A/ECHS) HQ Andaman & Nicobar Command (A/ECHS) AMA ECHS, Embassy of India, Nepal DIAV

for info and necessary instrs pl.
Yearly review of list promulgated
in 2016 can be issued when
considered appropriate.

for passing instrs to all Stn HQs, SEMOs and SEDOs

All Regional Centres -

- 1. PI ensure that a Physical copy of this docu is maintained at all ECHS PCs and all ranks are aware of the details.
- 2. Its implementation be checked by all visiting offirs.

<u>Internal</u>

All Secs

- 1. For info. Please maint a physical copy of this docu.
- 2. S & A Sec to upload on ECHS website.

....2/-

Tele: 23093481

By Hand/ Fax

Office of DGAFMS/ DG-2C Ministry of Defence Room No-48, 'M' Block New Delhi- 110001

19189//DGAFMS/DG-2C/CDL

DGMS (Army)

DGMS (Navy)

DGMS (Air)

MD (ECHS)



19 Apr 2016

1. References:-

- (a) Letter No 19189/DGAFMS/DG-2C/ CDL(Policy) dated 16 Oct 2012.
- (b) Letter No 20069/DGAFMS/DG-2C/ECHS EDL dated 05 May 2015.
- (c) Letter No 19189/ DGAFMS/DG-2C/CDL-2016 dated 18 Mar 2016.
- (d) Note No 43645/DGAFMS/DG-1C dated 18 Mar 2016.
- (e) Letter No 19189/ DGAFMS/DG-2C/CDL-2016 dated 12 Apr 2016.
- Two separate lists of drugs for CDL and EDL for ECHS were issued vide this
 Dte Gen letter under reference. As per feedback received from various stake
 holders, it was perceived that the CDL and EDL for ECHS have not achieved the
 desired clientele satisfaction.
- 3. In view of the above, a Board of Officers (BOO) was detailed by this Dte Gen to review the CDL and EDL. After taking into the consideration inputs from AFMS procuring agencies, World Health Organisation (WHO): Essential Medical Lists (EML), National Lists of Essential Medicines (NLEM) and CDL/ EDL of the other Govt Org, one Common Drug List (CDL) has been formulated by the BOO which has been duly approved by the Competent Authority. (List att as Appx 'A'). The Common Drug List (CDL) 2016 constitutes 474 Drugs and Consumables. 145 new drugs have been added and 42 drugs have been deleted.
- 4. The items in the newly formulated CDL are to be provided to all users units with maximum compliance by the respective DDOs/ Depots to ensure maximum clientele satisfaction among both Serving and ECHS clientele. This office will conclude Rate Contracts (RC) for all the newly included items subject to their annual drawl being more than Rs 20 lakhs. The same will be intimated subsequently.
- 5. The remaining Drugs and Consumables in PVMS and NIV for both ECHS and Serving Personnel not included in CDL will be procured locally by the respective Medical/ Dental/ ECHS CFAs within their delegated financial powers. All CFAs should make an all out effort for conclusion of Price Agreement for the above mentioned drugs and consumables required on recurring basis as per DPM-2009 and its Supplement 2010.
- In addition, AFMSD Mumbai, Lucknow and Delhi will continue to procure all Drugs & Consumables required for International Aid, Disaster Bricks and any other exceptional contingencies as hitherto fore.

7. This letter supersedes this Dte Gen letter No 19189/DGAFMS/DG-2C/t dated 16 Oct 2012 (CDL) and Letter No 20089/DGAFMS/DG-2C/ECHS EDL 05 May 2015 (EDL).

8. This has the approval of DGAFMS.

(SD Mulgund)

Brig

DDG AFMS (Stdn)

Encls: As above

Copy to/-

(All DDOs)

COMMON DRUG LIST - 2016

Appx 'A' (Refer O/o DGAFMS/DG-2C letetr No. 19189/DGAFMS/DG-2C/CDL dated 19 Apr 2016

_				v. valatura	-	AU
	PV	MS No		Nomenclature	No	
	0117	61		se 25 mg Tab	No	
2	1103	28		coumarol 4mg Tab	No	
3	011	502	Acetaz	olamide 0.25g Tab	Via	1
4	013	284	Acyclo	ovir 250 mg Inj	No	
5	-	280	Acycle	ovir 200 mg Tab	Bo	ett
6	-	2001	Acycl	ovir aphth oint 3% w/v (175mg) batt of 30 opticaps	В	ott
7	-	3285	Acycl	ovir Syp 400 mg/5ml	A	mp/Vial
8	-	1121	Aden	osine 3 mg/mi, 2 ml Inj		mp/Vial -
9	-	0301	Adre	naline Tartrate (1:1000), 1 ml lnj	N	lo
-	-	10801	Albe	indazole 400 mg Tab	F	Bott
-	-	10602	Albe	andazole Syp each 5 ml containing 200 mg bott of 10 ml Syp	-	No
		10000		ndronate Sodium 70mg Tab	-	No
1	100	11792		acalcidol Vit D3 0.25mcg Cap	-	No
L	2011	11955		opurinol 100 mg Tab	-	No
		10289		prazolam 0.25 mg Tab	-	No
L	-	012301	Air	trans-retinoic acid 10mg Cap		No
1		010885		mantadine 100mg Cap		
1	1000	010910	Ar	mikacin sulphate 250mg/2 ml inj		Amp/Vial/Vial
1	_	013222	A	miodarone HCl 150 mg, 3 ml lnj	_	Amp/Vial/Vial
1	19	011126	-	miodarone HCl 200 mg Tab		No
	20	011127				No
	21	NIV/01	- 10	unitriptyline Tab 25 mg		No
	22	011176	1	Amiodipine Besylate 5 mg Tab Amoxyclilin 1g + Clavulanic Acid 200mg, 1,2 gm lnj		Amp/Vial/Vial
	23	013208	1	Amoxycillin 1g + Clavulario Aced 28.5mg/5ml syp in 30 ml bo Amoxycillin 200mg/5ml + Clavulanic Acid 28.5mg/5ml syp in 30 ml bo	tt	Bott
	24	01320	4	Amoxyoillin 200mg/5ml + Glavulariic Acid 200mg/1nl		Amp/Vial/Vial
	25	-	5	Amoxycillin 250mg + Clavulanic Acid 50mg 300 mg Inj		No
	2	1000		as storie Acid 125mg Tao	afte	r Bott
				a managillo for oral susp containing Amoxycinin pass 725mg		
	2	7 01320)A	reconstitution (bottle of 55 mg		Amp/Vial
	2	8 0108	54	Amphotericin lipid complex 50mg Inj		Amp/Vial
	. 1	29 0106		Amphotericin-B 50 mg Inj		No
		30 0108	179	Anastrazole 1mg Tab		

S No	PVMS No	Nomenclature	A/U
31	011630	Antacid (chewable) containing dried Aluminium Hydroxide IP 250mg Mag Hydroxide NF 250mg Methyl Polysiloxane 50mg Tab	No
32	011632	Antacid Gel each 5ml containing dried Aluminium Hydroxide gel IP 250mg, Magn esium hydroxide NF 250mg and Methyl Polysiloxane 50mg Bottle of 170 ml	Bott
33	011653	Anti haemorhoidal Ointment containing Betamethasone 0.05% Phenylephrine 0.1% & lignocaine 2.5% tube of 15 gm with applicator	Tube
34	012630	Anti phiebitis cream Tube of 15g/ 20g	Tube
35	020001	Anti Venom, Serum polyvalent, Dry Vial of 10ml	Vial
36	011247	Anticarious Fluoride Rinse Mouth wash with sodium fluoride acidulated phosphate bott of 300-500 ml	Bott
37	011246	Antiseptic mouth wash containing Sodium fluoride & triclosan bott of 100- 150ml	Bott
38	011665 .	Antispasmodic cap containing Dicyclomine HCL 10mg, Dextroprop Oxyphen HCl 65mg Acetaminophen IP 460mg	No
39	0 13225	Artemether 80 mg + Lumefantrine 480 mg Tablet	No
40	010678	Artemether 80mg/ml, 1 ml Inj	Amp/Viel/Viel
41	NIV/01	Artesunste (A) + Sulphadoxine - Pyrimethamine (B) Combi pack (B) 1 Tab 25 mg (A) + 1 Tab (250 mg + 12.5 mg)	
42	010676	Arlesunate 50mg Tab	Pack No
43	010675	Artesunate 60mg Inj	Amp/Vial/Vial
44	012701	Ascorbic Acid 100 mg Tab	No
45	010253	Aspirin (Soluble) 350 mg Tab	No
46	011174	Aspirin 150 mg Tab	No
47	011164	Asprin 75 mg Tab	No
48	011142	Atenolol 25 mg Tab	No
49	11132	Atorvastatin 10mg Tab	No
50	011100	Atorvastatin 20 mg Tab	No
51	011802	Atracurium 10 mg/ml, 2.5 ml inj	Amp/Vial
52	010131	Atropine Sulphate 0.6 mg, 1 ml lnj	Amp/Vial
53	010701	Azathioprine Tab 50 mg	No
54	012104	Azelastine HCL 140 mcg + Fluticasone Propionate 50 mcg BP, Nasal spray	No
55	012810	Azelastine Hcl 140 mcg and Fluticasone furcate 27.5 mcg per dose (Nasal Spray)	Bott
56	013223	Azithromycin Dihydrate 250 mg Tab/Cap	No
57	012455	Beclomethasone Dipropionate 50 mcg and Levosalbutamol 50 mcg per metrad dose in CFC free MDI	No





S No	PVMS No	Nomenciature	A/U
58	013212	Benzathine penicillin 6,00,00 unit Inj	Amp/Vial
59	011306	Benzoyl Peroxide 2.5% Tube of 20 gms Tube	Tube
80	012111	Betahlstine Dihydro Chloride 8mg Tab	No
81	0 11397	Betamethasone dipropionate 0.025 % w/w, neomycln 0.5 % w/w, clotrimazole 1 % w/w Cream Tube of 20g	No
52	011311	Betamethasone Dipropionate USP 0.05mg and Gentamycin Sulphate 1mg/gm Tube of 5gm	Tube
53	011309	Betamethasone Cream containing Betamethasone Valerate 0.12% with Salicylic Acid 3.0% Cream tube of 20 gm	Tube
84	010870	Bicalutamide 50 mg Tab	No -
85	012086	Bimatoprost 0.03% bott of 3ml	Bott
66	011678	Bisacodyl 5 mg Tab	No
67	0 10530	Botulinum Toxin 100 u, 1 ml Inj	Amp/Vial
88	012020	Brimonidine Tartrate 0.2%, Eye drops	No
69	012487 ,	Bromhexine syp 5 ml containing 4 mg of Bromhexine Hol bottle of 100ml	Bott
70	010911	Bromocriptine 2.5 mg Tab	No -
71	012814	Budesonide 0.5 mg Resputes	No
72	010116	Bupivacaine HCl 5 mg/ml heavy 4 ml Inj	Amp/Vial
73	010115	Bupivacaine HCl 5 mg/ml, 20 ml lnj	Vial
74	010800	Busulfan 2mg Tab	No
75	011314	Catamine Powder	Kg
76	011963	Calcium acetate 500 mg Tab	No
77	012708	Calcium Carbonate 500mg Tab (elamental) and Vit-D-3-200iu to 250iu Tab	No
78	012712	Calcium gluconate 10%, 10 ml Inj	Amp/Vial
79	010806	Capacitabine 500mg Tab	No
80	270545A	Peritoneal Dialysis solution IP (1.5% for CAPD: 2 ltr Bag) with Minicap	Ltr
81	2705458	CAPD Fluid 2.5 % 5 itr bag	Ltr
32	010631	Capreomycin 0.75 gm Inj	Amp/Vial
33	012918	Capsacsin Gel Tube of 20gm	Tube
84	010538	Carbamazepine 200mg Tab	No
85	010540	Carbamazepine sys 100mg/5ml bottle of 100ml	No
86	011788	Carbimazole-5 mg Tab	No

S No	PVMS No	Nomenclature	A/U
-	010665	A Company of the Comp	Vlai
	011240	Cavity liner Calcium Hydroxide based self curing, Radiopaque two paste system Tubes of not less than 10 gms	Set
90	013243	Cefixime 100mg tab	No
91	012206	Cefixime Syp 50mg/5ml bott of 30 ml	Bott .
92	013226	Cefotaxime Sodium 1gm Inj	Amp/Vial
93	013229	Ceftazidime 1gm Inj	Amp/Vial
94	013230	Ceftriaxone 1gm Inj	Amp/Vial
95	011316	Cetrimide powder	Kg
96	012210	Cetrizine Syp 5mg/5ml bott of 60 ml	Bott
97	010302	Cetrizine-dihydrochloride 10mg Tab	No
98	010807	Chlorambucii 2.0mg Tab	No
99	011253	Chlorhexidine mouth wash 0.12% sugar and alcohol free bottle of 450-500 ml in amber coloured bottle	Box
100	010681	Chloroquine Phosphate 250mg Tab	No
101	010680	Chloroquine Phosphate Syp (containing 50mg base per 5ml) bottle of 60 ml	Bott
102	011465	Chtoroxylenol sol pot Hydroxide 13.6g, Chloroxylenol solution 50.5g Oleic Acid-7.5ml Castor Oll-63.0g Terpineal-100ml Ethanol (96%)-200ml Purified water Freshly bolled & cooled to produce 1000ml	Ltr
103	012115	Clonarizine 25 mg Tab	No
-	012005	Ciprofloxacin 0.3% eye drops of 3mg/ml bott of 5 ml	Bott
-	013236	Ciprofloxacin 200 mg/100ml Inj	Amp/Vial
-	6 013237	Ciprofloxacin 250 mg Tab	No
-	7 012009	Ciprofloxacin HCL 0.3% + Dexamethasone 0.1 % bott of 5ml	Bott
-	B 013241	Clarithromycin 250 mg Tab	No
-	9 011318	Clindamycin phosphate 1% topical gel tube of 10 gm	Tube
-	0 010541	Ciobazam 5 mg Tab	No
-	1 011320	Clobetasol Propionate Cream 0.05% in Tube of 10gm	Tube
-	2 010622	Clofazimine 100mg Cap	No
whole	3 011723	Clomlphene Citrate 50 mg Tab	No
-	4 010542	Clonazepam 2mg Tab	No
-	5 011180	Clonidine 100mcg Tab	No
-	6 011168	Clopidogrel 75 mg Tab	No
-	7 012122	Ciotrimazole 1% w/v IP+ Lignocaine 2% w/v IP ear drop bott of 10ml	Bott
-	18 010856	Ciotrimazole mouth paint 1% bottle of 15 ml	Bott

No	PVMS No	Nomenclature	A/U
119	011323	Clotrimazole Puly 1% Bott of 75gm	Bott
120	011739	Clotrimazole Vaginal Pessary 100mg	No
121	011250	Clove Oil bottle of 50ml	Bott
122	012314	Clozapine 100 mg Tab	No
123	011324	Coaltar Topical solution bottle of 1000 ml	Ltr
124	011272	Collagen with hydroxyapatite and chlorhexidine pack of 1 gm	Pack
125	011259	Collagen with medicaments, pack of 1 gm	No
126	010255	Common Cold Tab (Cetrizine 5-10 mg + Paracetamol 500 mg + Pseudoephedrine 30-60 mg)	No
127	012489A	Cough expectorant syp 5 ml containing Diphenhydramine Hcl 14.08mg ammonium chloride 0.138 gm, Sodium citrate 57.03mg, menthol 1.14 mg in flavoured syp base bott of 100ml	Ltr
128	012491	Cough sedative syp each 5 ml containing chlorpheniramine maleate 2.5mg guiaphenesin 100mg noscapine 15mg Södlum citrate 60mg in flavoured base bott of 100 ml	Ltr
129	NIV/01	Cremaffin white each 15ml containing milk of magnesia 11.25ml, liq Paraffin 3.75ml bottle of 170 ml	Bott
130	012008	Cyclopentolate HCI 1% Ophth soln bottle of 5MI	Bott
131	010812	Cyclophosphamide 50 mg Tab	No
132	010705	Cyclosporine A micro emulsion 25mg cap	No
133	010624	Dapsone 50mg Tab	No
134	011251	Desensitising paste (Stannous Fluoride / Pottasium Nitrate/Sodium monofluro-phosphate) Tube of 40-55 mi or gm	Tube
135	011007	Desferioxamine 500 mg Inj	Vial
136	010308	Dexamethasone 0.5mg Tab	No
137	010310	Dexamethasone Sodium Phosphate 4.4mg (Equivalent to Dexamethasone Phosphate 4mg/ml) 2ml Inj	Amp/vial
138	270151	Dextran 40, 10% v/v in 0.9% Sodium chloride solution bott of 500ml	Bott
139	012506	Dextrose 50%, 25 mi Inj	Amp/Vial
40	012507	Dextrose Inj 25%, 25 ml Inj	Amp/Vial
41	010544	Diazepam 10 mg, 2 ml inj	Amp/Vial
42	010547	Diazepam 5 mg Tab	No
43	010258	Diciofenac 25 mg/ml IP, 3ml Inj	Amp/Vial
44	012920	Diclofenac gel 1% Tube of 30 gm	Tube
45	010257	Diclofenac Sodium 50 mg, enteric coated Tab	No
46	011660	Dicyclomine HCI 20mg Inj	Amp/Vial
47	011727	Dienoestrol 0.01% vaginal Cream Tube of 50 g	Tube

S No	PVMS No	Nomenclature	A,
-	010611	Diethylcarbamazine 50mg Tab	No
	011155	Digoxin 0.25 mg Tab	No .
50	012216	Digoxin Syp/Elixir 0.05mg per mi in 30 ml packages	Bott
51	011105	Diltiazem (Controlled Delivery) 90mg Tab	No
152	011732	Dinoprostone Gel 0.5 mg (In 3gm/2.5ml gel)/ syringes	No
153	011162	Dobutamine HCl 250 mg, 5 ml Inj	Amp/Vial
154	011645	Domperidone 10 mg Tab	No
_	012215	Domperidone Syp 1mg/ml bott of 30 ml	Bott '
-	010545	Donepezil 5mg Tab	No
-	011161	Dopamine HCl 40 mg/ml, 5ml Inj	Amp/Vial
-	013244	Daxycycline cap 100mg	No
	011724	Doxylamine Succinate 10mg USP + Pyridoxine Hydrochloride 10mg IP Tab	No
160	011248	Gel for root canal preparation containing water soluble lubricant 15-17% EDTA, Tube of 3.0-5.0 gm	PFS
161	011193	Enalapril 5 mg Tab	No
162	011673	Enema Sodium phoshate ml 6% sod Acid phoshate 16% pack of 100ml	No
163	011170	Enoxaparin 40 mg/0.4ml Inj	PFS
-	011171	Enoxaparin 60 mg/0.6ml Inj	PFS
-	5 0 11627	Entecavir Tab 0.5mg	No
-	8 011010	Erythropoeitin 10,000IU Inj	Vial/PFS
-	7 011009	Erythropoeitin Human Recombinant, 2000 IU	PFS
-	8 012318	Escitalopran 10 mg Tab	No
-	9 011130	Esmolol 100 mg, 10 ml inj	Amp/vial
-	0 010638	Ethambutol 200mg Tab	No
-	1 012818	Ethambutol 800mg Tab	No
-	2 010105	Ether Solvent	Ltr
-	3 012820	Ethionamide Tab250 mg	No
-	4 012469	Etophylline 115mg and Theophylline 35 mg in slow release form Tab	No
17	5 010820	Etoposide 50mg cap	No
-	6 012951	Etoricoxib 90mg Tab	No
-	77 011984	Everolimus 0.75 mg Tab	No -
-	78 011039	Factor IX 600 unit inj	Amp/Vial
-	79 0 11021	Factor VIII Inj 250 iu	Amp/Vial

lo	PVMS No	Nomenclature	A/U
-	011106	Fenofibrate 200 mg Tab	No
81	010742	Fentanyl 25mcg Transdermal	Patch
82	0 11004	Ferric hydroxide sucrose complex 20 mg in 5mL for injection	Amp/Vial
1100	011012		No
84	010305	Suspension Fexorenadine 30mg/5ml 60 ml bottle	Bott
85	012694	Finasteride 5 mg Tab	No
86	012012	Fluconazole 0.3% w/v bott of 5 ml	Bott
87	010660	Fluconazole 150 mg Cap/Tab	No:
88	010658	Fluconazole 50 mg cap/tab	No .
189	012319	Fluoxetine HCL 20 mg cap	No
190	012013	Flurbiprofen sodium opthalmic sol 0.3% vail of 5ml	Amp/Vial
191	012830	Fluticasone propionate inhaler for paed use 50mcg/Dose, 120 metered doses	No
192	011014	Folic Acid 5 mg Tab	No
193	012835	Formeterol 6 mcg and Budesonide 400 mcg CFC free MDI, 120 metered doses	No
194	011332	Framycetin sulphate Cream BP 1% Cream 100 gms	Tube
195	012661	Framycetin sulphate gauze Box of 10	Box
196	011508	Frusemide 20 mg, 2 ml ln)	Amp/Vial
197	011507	Frusemide 40 mg Tab	No
198	010548	Gabapentin 300 mg Cap	No
199	011336	Gamma Benzene Hexachloride 1% w/v Cetrimide 0.1% w/v in alcoholic solution	Ltr .
200	011954	Gancyclovir 250mg Tab	No
201	010833	Geftinib Tab 250 mg	No
202	013248	Gentamycin sulphate inj IM/IV 40mg/mi, 2 mł inj	Amp/Vial
203	011762	Glimepiride 1mg Tab	No
204	011763	Glimepiride 2 mg Tab	No
205	012925	Glucosamine 250mg + Chondroitin Sulphste 200mg Cap	No
208	270313	Glucose saline isotonic solution self collapsible bags dextrose 5% with 0.9% Sod chloride	Bott
207	270302	Glucose solution 5% in non-toxic disposable plastic bott of 500ml FFS or equivalent technology	Bott
200	011470	Gluteraldehyde 2% with OPA with checking strips	Ltr
209	011674	Glycerine Suppositories child size (2g Mould)	No
21	011806	Glycopyrrolate 0.2 mg/ml, 1ml trij	Amp/Vial
21	010875	Goserelin 3.6 mg Prefilled Syringe	PFS

	D) (110 1)	Nomenclature	LIVA
0	PVMS No 011715	Gosedin 10.8 mg Ini	Amp/Vial
-	010857	Granulocyte Colony Stimulating Factor 300mog inj	PFS/Vial
		Haemostatic sponge gelatin 80 mm long, 50mm broad 10 mm thick	Piece
	012660	Haloperidol 5mg/ml Inj	Amp/Vial
	012324	Heamatinic Tab/Cap containing (a) Ferrous fumerate 200 mg to 350m mg (b) Vit B12 2mcg to 10 mcg (c) Folic Acid 500 mcg to 1500 mcg	No
17	011025	Heparin 5000 IU/ml Inj	Amp/Vlal
	012017	Homatropine Hydrochloride, Sol 2%	Bott
	011611	Human Albumin 20% In bott of 100ml	Bott
_	011793	Human Chorionic Gonadotrophin 2000 IU Inj	Amp/Vial
	011767	Human Insulin Analogue long acting basal Inj 100ml IU/ml (Recombinant DNA origin) 300 IU Disposable Pan with 5 needles per pen	Pen
22	2 011766	Human Insulin Analogue Rapid acting Inj, 100 IU / ml (Recombinant DNA origin) 300 IU Disposable Pen with 5 needles per pen	Pen
22	3 011181	Hydrochlorothiazida 25mg	No
_	4 011658	Hydrocortisone Enema 10% w/v	Can
-	5 010314	Hydrotortisone Sodium Succininate 100 mg Inj	Amp/Vial
-	6 011472	Hydrogen peroxide solution with stabilizer IP (20 volume) 500 ml Bott	Ltr
-		Hydroquinone 2% Tube of 60 gm	Tube
		Hydroxy Ethyl starch 6% soln bott of 500 ml	Bott
-	28 012515 29 012926	Hydroxychloroquin 200mg Tab	No
1	30 010826	Hydroxyurea 500mg Cap	No
	31 011689	Hyoscine Bromide Inj 20 mg/ml,1ml Inj	Amp/Visl
1	32 010259	Table Table	No
100	33 010261	The second section of 50 ml	No
1	34 010834	The second Control of	No
-		and the state of the Control of the	No
-	235 010863	AL OB A Firm Tob	No
1	236 011184	The second secon	Amp/vial
-	237 010845	Insulin Highly Purified human natural 401U/ml, 10 ml Inj	Amp/vial
1	238 011774	Inj Human Insulin Analogue Aspart Premix 30% insulin 770% insulin protamine aspart suspension 100 IU/mi (Monocomponent Insulin	PFS/PFP
+	240 01171	Inj Human Insulin Analogue Premix 25% insulin lispro / 75% Insulin lispro Inj Human Insulin Analogue Premix 25% insulin lispro Insulin, recombinant I	ONA PES/PEP

N	PVMS N	Nomenclature Nomenclature	A/U
24	1 011764	Insulin Premixed biphasic 40 iu per ml (30% human neutral plus 70% human isophane insulin), 10 ml lnj	Amp/vial
24	2 012470	Ipratropium Bromide Respirator soln 500 mcg/2 ml respule	No
24	012714	Iron Syp Paediatric each 5 ml containing minimum 25 mg Elemental Iron, Folic Acid-minimum-0.5 mg and Vit 812-minimum-5 mcg with or without multivitamins in a bott of 100ml	Bott
244	011676	Isapgol/ispaghula husk 3,5 g/n	Sachet
245	010108	Isoflurane Bottle of 100 ml	
248	010640	Isoniazid 100mg with Pyridoxine 5mg Tab	Bott
247	010841	Isoniazid 300 mg Tab	No
248	012222	Isoniazid syp 100mg/5ml 120ml bott	No Bott
249	011108	Isosorbide Dinitrate 10 mg Tab	No
250	011109	Isosorbide-5 Mononitrate 20 mg Tab	No
251	011743	Isoxsuprine 10mg Tab	No
252	011744	Isoxsuprine HCl 5mg/ml arrip of 2 ml	Amp/Vial
253	NIV/01	Ropride 50mg Tab	No
254	010668	Itraconazole 100mg Cap	No
255	010604	Ivefmectin Tab 6mg	No
256	010109	Ketamine HCI 50 mg/mi, 2 mi inj	Amp/vist
257	011340	Ketoconazole lotion 2% bott of 75 ml	Bott
258	012019	Ketorolac Tromethamine 8.4%, Eye drops	Bott
259	011146	Labetalol HCL 10/2 mm Talk	Na
260	011680	Lacturese eve pach Say population 2 and 1 to 5 and	Bott
61	010563	Lamotricine 25mo Tab	No -
62	012022	Latanoprost 0.005% with 0.5% Tomotel and 1.00 an	Bott
63	012946	Leffunomide 10mo tab	No
64	010876	Letrozole 2 5mo Tah	No
65	010534	Levetiracetam 100 mo/ml. Sur/Soln@invid	3ottle
66	010303	Levo cetrizine Smn Tah	Vo
67 (10917	Levodopa 250 mg with Carbidopa 25 mg Tab	vo Vo
88		Levofloxacin-500 mg Tab	lo
9 0	11746	evonomeetral 0.75 mg + Chilade-teach 2.55	'kt
0 0		Levo-Salbutamol 1 25mg + Incotroption 500	0

S No	PVMS No	Nomenclature	LIVA
	012862	Levo-Salbutamol 50 mcg + Ipratropium 20 mcg metered dose inhaler, 200 dose units	No
272	012475	Leve-Salbutamol aerosol inhalation pack of 200 metered dose (each metered dose supplies 50 mcg of Leve-Salbutamol)	No
273	0 12246	Levo-Salbutamol syrup 1 mg/5mi bottle of 100 ml	Bott
274	010128	Lignocaine 100 mg & Ethanol 28 mg/ml v/v spray container of 500/800 ml	No
275	010121	Lignocaine Hcl 2% with Adrenaline(1:80000) 30 ml Inj	Amp/vial
	010119	Lignocaine HCl 2%(without Adrenaline) 30 ml Inj (suitable for ophthalmic use also)	Amp/vial
277	010129	Lignocaine HCI Jelly 2% Tube of 30 gm with plastic nozzle	Tube
ineriots.	012026	Lignocaine Hyrochloride 4% topical solution bott of 30 ml	Bott
27!	NIV/01	Linagilptin 5mg Tab	No
28	0 012606	Linezolid 600 mg Tab	No
-	1 011330	Liquor Formaldehyde 40% w/v	Ltr
28	2 010805	Lomustine 40mg Cap	No
28	3 010543	Lorazepsm 2mg/ml, 2 ml lnj	Amp/Vial
28	4 011186	Losartan 25 mg Tab	No
28	5 011671	Mabeverine HCI (135mg) Tab	No
-	6 011758	Magnesium sulphate 50% w/v Inj	Amp/Vial
28	37 011513	Marenitol 20% inj bettle of 350 ml inj	Bott
25	88 V013090	Mecobalamin with B-Complex, Vial of 30 ml, Inj *	Amp/Vial
-	89 011749	Medroxy progesterone 10 mg Tab	No
-	90 010682	Mefloquine 250mg Tab	No
2	91 010837	Melphalan Tab 5 mg	No
-	92 010839	Mercaptopurine 50mg Tab	No
2	93 012608	Meropenem 1 gm Inj	Amp/vial
2	94 011784	Metfornin 0.5g Tab	No - ' -
2	95 011708	Tab Metformin SR 1 g	No
2	96 011707	Tab Metformin SR 0,5gm	No ·
2	97 010843	Methotrexate 2.5mg Tab	No
	98 012029	Methyl Celluliose 2% solution bottle of 5 ml	Bott
-	99 012934	Methyl Prednisolone Sodium Acetate 80 mg Inj	Amp/Vial
- 10	100 010721	Methyl Prednisolone Sodium Succinate 1000mg Inj	Amp/Vial
-	011194	Metryldopa Tab 250mg	No

S No	PVMS No	Nomenclature	A/U
302	011750	Methylergometrine malente 0.2mg, 1 ml Inj	Amp/Vial
303	011177	Metoproloi - Extended release 50mg	Tab
304	010673	Metronidazole 400 mg, Tab	No
305	013253	Metronidazale Inj for IV use containing 500mg per bott of 100 ml	Bott
306	012228	Metronidazole susp 200 mg/5ml bott of 50 ml	Bott
307	010135	Midazolam 5 mg, 1 ml Inj	Amp/Vial
308	011726	Mifepristone 200 mg Tab	No
309	011347	Minoxidil 5% lation bott of 60ml	Bott
310	011703	Misoprostrol 25 mcg, Tab	No
311	011345	Mometasono 0.1% Tube of 10 gm	Tube
312	012846	Monteleukast 5 mg Tab	No
313	010284.	Morphine 15 mg, 1 ml inj	Amp/Vial
314	012721	Multivitamin drops with constituents having Vit A-1400-1600 IU/ml, Vit B1-0.3-0.6 mg/ml, Vit B2-0.3-0.8 mg/ml, B6-0.2-0.6 mg/ml, Vit C-20-30 mg/ml, Vit D-200-400 IU/ml in Bottle of 15ml	Bott
315	011346	Mupirocin 2% Oint Tube of 5 gm	Tube
316	010725	Mycophericiate mofetil 500mg Tab	No
317	012232	Nalidixic acid 300mg/5ml bottle of 30 ml susp	Bott
318	010273	Naproxen 250mg Tab	No
319	012135	Nasal Decongestant adult drops (Xylometazoline HCL 0.1% w/v nasal drop) bottle of 10 ml	Bott
320	011731	Natural Micronised Progesterone 100 mg Tab	No
321	011826	Neostigmine 0.5 mg, 1 ml lnj	Amp/Vial
322	011113	Nicorandii 10 mg Tab	No
123	010319	Nor adrenatine Siterirate 2 mg/ml, 2 ml Inj	Amp/Vial
324	011752	Nor-Ethisterone 5mg Tab	No
25	012235	Norflox Syp 100mg/5ml bott of 30 ml	Bott
26	013255	Norfloxacin 400mg Tab	No
27	011753	Obstetric antiseptic cream containing Dichloroxylenol 1% Terpineol 1% Phenol 0.25% in lubricunt base	Kg
28	011754	Oestrogen Conjugated () 525mg Tab	No
29	012360	Olanzapine 10 mg Tab	No
30	010872	Ondansetron 8 mg Tab	No
31	010871	Ondansetron 8mg (n)	Amp/Vial
32	012238	Ondansetron Syp 2 mg/5ml in bott of 30 ml	Bott

No.	PVMS No	The state of the s	
	011688	Oral Rehydration powder sachet of 20.5 g each containing Sortium obtariote	A/U
333	011688	IP 2.6 g Anhydrous Destrose IP 13.5 g, Potassium chloride IP 1.5 g & Sodium citrate IP 2.9 gm to make the mixture	Sachet \
334	011692	Ornidazole 500mg + Offoxscin 200mg Tab	No
335	010536	Oxcarbazepine 150nig Tab	No San Maria
336	011756	Oxytocin 5 units per 1.0ml amp inj	Amp/Vial
337	011689	Pancreatin Microsphones 150mg Cap	No.
338	011830	Pancuronium bromide 2 mg/ml, 2 mi loj	Amp/Vial
339	011638	Pantoprazole 40mg Inj	Amp∕Viai
340	011637	Pantoprezole 40mg Tab	No
341	NIV/01	Para dichlorobenzen 2% w/v Benzocaine 2.7% w/v Chlorbutol 5%, Turpentine oil 15% w/v cott of 10 ml	Bott
	010278	Paracetamol 325mg and fluprofen 400mg Tab	No
343	010275	Paracetamol-500mg Tpb	No
344	010277	Paracetamol Syp 125 mg/5 ml bost of 60 ml	Life
345	011358	Paraffin Soft yellow Jaz of 4 Kg	Ка
346	011682	Parraffin Liq in bottle of 100 ml	Ltr
347	011606	Pegylayted Interferon ALFA 2B 80-180 mog Inj	PFS
348	011195	Perindopril 4mg Teb	No
349	011273 -	Periodontal Pack (non sugenol) two pasts system of base & catalyst 90 gm each	Pack
350	270552	Peritonial Dialysis Carherer set adult i) Stainless steel trocar 25cm long with PVC guide and suitable holder for easy operation. Ii) Multi hole open ended Catherer.	Set
351	011350	Permethrin 5% Tube of 30 gm	Tube
352	010287	Pethedine 50 mg, 1 ml inj	Amp/Vial
353	010320	Pheniramine Maleate 25 mg Tab	No.
354	010318	Pheniramine Malente In: 22.75 mg par mt amp of 2 mi	Amp/Viat
355	012036	Phenylephrine HCI 10% with Chlorbutol 0.5% eye drops	Viel
56	010553	Phenytoin oral suspension centaining Phenytoin 100mg/4ml bottle of 100 ml	A CONTRACTOR OF THE PARTY OF TH
57	010554	Phenytoin Sodium 100 mg Tab	No /
58	010552	Inj Phosphenytoin 75mp/ml-2ml empoure	Vial
59	011040	Phytomenadione (Vit K) i mg/0.5ml inj	AmpAlial
60	012038	Pilocarpine Nitrate eye solution 2% bolt of 5 ml	Bott
61	013258	Dispersion 4 and 1991	Any 1
82	011352	Podaphyllin resis solution 10%	/ /



S No	PVMS No	Nomenclature	A/U
363	011683	Polyethylene glycol (Purgative powder) IP 118gm. Sod Chloride 2.93 gm, Pot Chloride 1.484 gm, Sod Bicarb 3.37 gm, Sod sulphate 11.35gm	Sachet
364	011261	Post Extraction resorbable fiber based alveolar dressing, jar of 10-12 gms	Jar
365	012518	Potassium Chloride 15% Inj (IV) amp of 10 ml (1.5gm)	Amp/Vial
366	012685	Potassium Citrate 1100mg, citric Acid or Mag citrate 300 to 400mg per 5ml bott of 200ml	Bott
367	011741	Povidone Iodine 200 mgm Pessary	No
368	010431	Pralidoxime 500mg/20ml Inj	No
369	V013118	Praziquantel 50 mg, Febantel 150 mg pyrantal embonate 144 mg Tab	No
370	011189	Prazosin 2.5mg sustained release/slow release Tab	No
371	010322	Prednisolone 5 mg Tab	No
372	012243 -	Prednisolone Syp 5mg/5ml in bott of 30 ml	Bott
373	0 10533	Pregabalin 75 mg Tab/Cap	No
374	010683	Primaquine (7.5mg base) Tab	No
375	010849	Procarbazinę HCI 50mg Cap	No
376	010307	Promethazine Syp 5mg/5ml Bott of 60 ml	Bott
377	012347	Prometházine HCl 25 mg Tab	No
378	010110	Propofol 1% or 10mg/ml, 20 ml lnj	Amp/vial .
379	0 11151	Propranodol TR 40mg Tab	No
380	011030	Protamine Sulphate 1% , 5ml Inj	Amp/Vial
381	011972	Protein Supplement Formula for Renal Patient	Sachet
382	011262	Pulp Devitaliser Non Arsenic containing Paraformaldehyde 46% Lidocaine Base 37% Phenol 6% paste, Jar of 4.5 gm	Jar
383	010610	Pyrantel Pamoate 250 mg/5ml susp.	Bott
384	010644	Pyrazinamide 0.5 gm Tab	No ·
385	010643	Pyrazinamide Suspension 250 mg/5ml, Syr, Bottle of 100 ml	Bott
386	010686	Quinine 300mg Tab	No
387	011191	Ramipiril 5 mg Tab	No ,
388	011640	Ranitidine 150 mg Tab	No
389	012070	Inj Ranibizumab 2.3mg/ 0.23 ml	Amp/Vial
390	0 11711	Recombinant Human Growth Hormone 5mg to 15mg, Inj	PF Syringe/ Pen
391	0 11001	Recombinant human tissue-type Plasminogen activator (tPA) powder for injection 20mg	Amp/vial
392	011609	Ribavirin Cap 200 mg Cap	No
393	0 10630	Rifabutin 150 mg, Cap	No

	S No PVM	S No	19189/DGAFMS/DG-2C/CDL dated	19 Apr
	94 01063	-	Rifampicin 150mg Cap	A
3	95 010636			No
3	96 01063	7	Rifampicin 450mg + Isoniazid 300mg combination Cap/Tab	No
3	97 010632	2	Rifampicin 600 mg+Tab INH 300mg Tab	No
-		-	Rifampicin oral susp 100mg/5ml bottle of 200 ml	Bott
-	98 270715		Sodium lactate compound solution (Ringer lactate solution) in nontoxic disposable plastic bottle of 500ml FFS	Bott
		-	Risperidone 1mg/ml Syp in bottle of 30 ml	Bott
	0 010850	-	Rituximab 500mg Inj ,	Amp/Vial
-	1 010568	-	Rizatriptan 5mg Tab	No -
40	2 011356	-	alicylic Acid 3 - 5% and Coal tar 1 - 3% soln, Bott	
40	0 12856	R	almeterol 50mcg + Fluticasone 250 mcg pulverised for inhalation otacaps, Pack of 30	Bott No
404	4 012858	S	almetrol 50mcg + Fluticasone 250mcg multi dose dry powder inhaler of 60	
405	012368		ertraline 50 mg Tab	Dose
406	011981		evelamer 400mg tab	No
407	010114		svoflurane Bottle of 250 ml	No
408	012684		Idenafil cltrate 50 mg Tab	Bott
409	011363		ver sulphadlazine 1% cream w/v Jar of 500 gms	No
410	011768	* Sit	agliptin Phosphate, 25 mg Tab	Jar
411	012525		dium Bicarbonate 7.5% amp of 10 ml	No
412	012103			Amp/Vial
		So	dium Chloride 0.65% w/v Nasal drops of 15 ml	Bott
+13	270714		dium chloride solution Isotonic in nontoxic disposable plastic bottle of Oml FFS	Bott
	011252	Ant	icaries Fluoride Gel containing sodium fluoride/Stannous Fluoride /Tube of 120-150 ml or gm	Bott/Tube
-	011163		llum Nitroprusside 50 mg Inj	Amp/Via!
-	011681	Sod	ium Phosphate solution 45ml each pack of 2 hours	Pack
17	010560	Sod	ium Valproate 200 mg Tab	No
	010559	Sodi	um Valproate oral solution 200mg/5ml Bott of 100 ml	
19 1	VIV/01	Sofo	sbuvir Tab 400 mg	Bott
0 0	11518	Spire	onolactone 25 mg Tab	Vo /
1 0	12528		le water for amp of 10 ml	lo
2 0	11165		otokinase 15 Lacs IU Ini	mp/Via
3 0	11840		invichibline Chloride 50 material 2	mp
4 0	11639		alfate Suspension 1gm/5ml bott of 200 ml	/
5 01	10677	Sulph	adoxine 500 mg & Pyrimethamine 25 mg Tab	/

ly

S No	PVMS No	Nomenclature	A/U
426	013260	Sulphamethoxazole 200 mg and Trimethoprim 40mg per 5ml bottle of 50ml Suspn	Bott
427	013261	Sulphamethoxazole 400 mg & Trimethoprim 80mg Tab	No
428	10565	Sumatriptan 50 mg Tab	No
429	010858	Sunitinib 12.5 mg Tab	No
430	010859	Sunitinib 25 mg Tab	No
431	0 11979	Tacrolimus 1 mg Tab	No
432	0 11980	Tacrolimus 0.5 mg Cap	No
433	010880	Tamoxifen Citrate 20 mg Tab	No
434	012686	Tamsulosin HCL 0.4mg Cap	No
435	012602	Telcoplanin 200 mg Inj	Amp/vial
436	011182	Telmisartan 40 mg, Tab	No
437	011172	Telmisartan 40mg + Amlodipine 10 mg Tab	No
438	010854	Temozolamide 100mg Cap	No
439	010855	Temozolamide 250mg Cap	No
440	0.11624	Tenofovir Tab 300 mg	No
441	011791	laj Teriparatide 750 mcg/ 3 ml	No
442	010856	Thalidomide 50 mg Tab	No
443	010111	Thiopentone-Inj of 0.5 g without water for Injection	Amp/vial
444	011706	Tab Thyroxine 50 mcg	No
445	011789	Thyroxine Sodium 0.025 mg Tab	No
446	011790	Thyroxine Sodium 0.1mg Tab	No
447	012053	Timolol Maleste eye drop 0.5% bott of 5 ml	Bott
448	010674	Tinidazole 500 mg Tab	No
449	010292	Tizanidine 2mg + Ibuprofen 400mg Tab	No
450	012054	Tobramycin 0.3% bott of 5MI	Bott
451	010567	Topiramate 25 mg Tab	No
452	0 11115	Torsemide 10 mg (Scored Tab)	No
	012656	TPN for Peripheral Vein Pack of 1000-2500 ml containing: Calorie 600 K cal/L, Amino Acid 22 gms/L Nitrogen 3.5 gm/L or more, glucose 65 gm/L, Lipid, 20 gm/L, Osmalarity not more than 900 milli osom/L	Bag
454	010293	Tramadol HCL 50 mg Cap/Tab	No
455	010294	Tramodol HCL 50 mg/ml Inj, 1 ml Amp	Amp/Vial
456	011034	Tranexamic Acid 500mg Tab	No
457	011377	Tretingin 0.05% Tube of 20 gm	Tube

5 V Florence

S No	PVMS No	Nomenclature 1	The second
458	011271	Triamcinalone Acetate 1% for oral use, Tube of 5 gm	A/U
459	011520	Triamterene 50mg IP and Benzthlazide 25 mg NFC (US) Tab	Tube White
460	012252	Triclofoe Sun Egg	No 103810
461	010926	Trihexyphenidyl HCl 2mg Tab	Bott SEED Y
462	011355	The state of the s	No ess
463	012058	Trioxasalen topical 0.2% bottle of 15 ml	Bott
	011379	Tropicamide Eye solution 1%, bott of 5 ml	Bott
		Urea cream, Urea 10 to 12% lactic Acid 5 to 10% in pack of 50 gm	Gm
	011607	Ursodexycholic acid 150mg Tab	No
466	013265	Vancomycin-CP 500 mg Inj	Amn/vial
167	011850	Vecuronium Bromide 4mg/ml, 1 ml Inj	Amp/Vial
168	012734	Vit D-3, 60,000 U per 1 om sachet	Sachet
169	012705	Vitamin B complex with a minimum concentration of vit B1-5mg, Vit B6-3mg & Vit B12-5mcg therapeutic Tab/Cap	
70	011175	Warfarin 5 mg Tab	No
71	012145	Xylometazoline HCl 0.05% w/v nasal solution for paed use bott of 10ml	
72		Zidovudine 300mg+ Lamivudine 150mg Tab	Bott
		Zoledronic acid 5 mg Inj	No
74	STATE OF THE STATE	Zolpidem 10 mg Tab	Amp/vial/PFS
-			No

R

Encl 2 (Refer to Para 10(n))

SAMPLE CALCULATION SHEET OF MMF FOR THE FIN YEAR 2019-20.

Ser	Ledger	PVMS/	Nomenclature		Month wise consumption													Monthly	%	Value	Value	Value	Value	Remarks
No	Vol/	NIV No														months	expdr	avg	variati	after	when	Rec	Vetted	
	Page			Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec			(g/f)	on	variati	adjusted	by PC	by	
	No			18	18	18	18	18	18	18	18	18	18	18	18					on	as per		SEMO	
1,			4.5																	۵.	packing	١,,	١.,	, ,
(a)	(b)	(c)	(d)													(t)	(g)	(h)	(j)	(k)	(I)	(m)	(n)	(p)
1.	1/3	011761	Acarbose 25mg Tab	205	240	308	426	378	<u>0</u>	<u>0</u>	426	365	300	325	265	10	3238	323	-	323	320	320		
2.	2/5	011014	Folic Acid 5 mg Tab	325	411	400	368	349	295	325	369	285	305	270	310	12	4012	334	-5%	314	-	315		Various packges
3.	1/18	010275	Paracetamol 500mg Tab	325	308	526	<u>112</u>	<u>0</u>	<u>0</u>	522	488	398 +50	275	330	345	09	3567	396	+5%	415	420	420		

Method of calculation/Entries

- 1. While the detailed procedure has already been explained, sample docu is attached for better understanding and assimilation.
- 2. Entries in columns:-
 - (a) Ser Nos to be entered starting from 1.
 - (b) Ledger Vol/Page No to be entered viz ledger vol 1/2/3 in first portion and concerned page No in second portion. Page No of latest ledger Vol in use to be mentioned. Previous Vol No/ Page No should be linked on the Ledger sheet.
 - (c) PVMS/ NIV No as applicable to be mentioned.
 - (d) Nomenclature in dictionary alphabetic sequence should be listed. In case of same name, low weightage medicine should be mentioned first.
 - (e) (i) Monthwise consumption should be correctly entered from ledger entries. Only that medicine should be entered which has been consumed by patients.
 - (ii) Since medicines from ALC are being issued to patients and only those are being taken on master ledger which are not being collected by month end, separate register maint for ALC should be used to take data of medicine consumption from ALC as well. It should be put with '+' mark as shown in Ser 3 for month of Sep 18. In case a medicine is not issued from ALC, it will be assumed as 'zero' and no entry to be maintained.

- (iii) If 'NA' medicines are purchased on reimbursement basis, a separate register will be maintained for the said purpose and medicines consumed by patients on acct of this will also be factored when implemented with addl entry as done for ALC medicines.
- (iv) Having made the entries, months having '0' consumption/ months where medicine got over in the middle of month will be underlined in 'red' and will not be factored in subsequent calculation. See example wherein '0' has been underlined as well as entry of Apr 18 in Ser 3 and No of months have been accordingly calculated. Values of this month will also not be factored in total.
- (f) Only those No of months to be put which have natural consumption when medicine has been available in the stock viz in Ser 1, '10' has been put taking out Jun 18 & Jul 18 where as '9' has been put in Ser 3 taking out May 18 & Jun 18 for '0' consumption and taking out Apr 18 as ledger bal had shown 'NIL' in this month in the middle of month.
- (g) Total of only those months to be taken where normal consumption exists. In case of the months as per (e)(iv), their total should not be done. Total to be done for those months as given in (f).
- (h) Avg be taken by (g)/(f) entries. Avg be put in whole Nos. Decimals not to be used.
- (j) A conf should be held with all med/Para med/ Para dental pers incl doctors & specialists to deliberate on the need to increase/ decrease the value reached. Entries of variation to be made for each medicine but be limited to 0 to 10%. Reasons of such variations should be recorded at PC end for future reference. Higher changes should be justified in remarks coln.
- (k) Value of (h) be modified (increased/ decreased) as per % in (j) column and fresh value be recorded in whole Nos.
- (I) Value reached in (k) to be modified upwardly/ downwardly to nearest smallest packing where uniform packs come. Various companies may be packing different No of tablets in the packs and in such cases no changes should be done. '__' should be placed in all such cases and values of coln (k) should be taken to closest of '5' and entered in (m) column. viz value for Ser 1 comes in (k) as 323 but has been modified as 320 as lowest packing of Acarbose 25mg tab is 10 tablets in a packet. As against this since Folic Acid 5mg comes in varying packing, '__' has been put in 2(I) and value taken as '315' closest to multiple of 5 in (m) column.
- (m) This columns should include value as recommended by PC. If a particular medicine is being hardly consumed / not required, value can be put 'zero' and reasons give in remarks coln. Except in such cases, value as obtained in (I) should be put in (m) as well.
- (n) Value as vetted by SEMO/SEDO could be same as given in (m) or less/ more as considered appropriate.
- (p) Any explanatory notes.



www.echs.gov.in

TOLL FREE: 1800 114 115